Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
  3. Corresponding author: Ramin Mojtabai, MD, PhD, MPH, 624 N. Broadway, Room 797, Baltimore, MD 21205 ([email protected]).
  4. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  5. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
  6. Department of Psychiatry, College of Physicians and Surgeon, Columbia University, and New York State Psychiatric Institute, New York, New York
  1. Mojtabai R. Nonremission and time to remission among remitters in major depressive disorder: Revisiting STAR*D. Depress Anxiety. 2017;34(12):1123–1133. PubMed CrossRef
  2. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41–50. PubMed CrossRef
  3. Thase ME. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am J Manag Care. 2001;7(suppl):S377–S385. PubMed
  4. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMed CrossRef
  5. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501–1504. PubMed CrossRef
  6. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Am J Psychiatry. 2010;167(10):1.
  7. Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry. 2019;53(2):109–118. PubMed CrossRef
  8. Masse-Sibille C, Djamila B, Julie G, et al. Predictors of response and remission to antidepressants in geriatric depression: a systematic review. J Geriatr Psychiatry Neurol. 2018;31(6):283–302. PubMed CrossRef
  9. Mojtabai R, Amin-Esmaeili M, Spivak S, et al. Remission and treatment augmentation of depression in the United States. J Clin Psychiatry. 2021;82(6):21m13988. PubMed CrossRef
  10. Zisook S, Johnson GR, Tal I, et al. General predictors and moderators of depression remission: a VAST-D report. Am J Psychiatry. 2019;176(5):348–357. PubMed CrossRef
  11. Steffen A, Nübel J, Jacobi F, et al. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. BMC Psychiatry. 2020;20(1):142. PubMed CrossRef
  12. Gill D, Hatcher S. Antidepressants for depression in people with physical illness. Cochrane Database Syst Rev. 2000;(2):CD001312. PubMed
  13. Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety. 2018;35(7):668–673. PubMed CrossRef
  14. Godin O, Bennabi D, Yrondi A, et al; FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) Collaborators. Prevalence of metabolic syndrome and associated factors in a cohort of individuals with treatment-resistant depression: Results from the FACE-DR study. J Clin Psychiatry. 2019;80(6):19m12755. PubMed CrossRef
  15. Chan KL, Cathomas F, Russo SJ. Central and peripheral inflammation link metabolic syndrome and major depressive disorder. Physiology (Bethesda). 2019;34(2):123–133. PubMed CrossRef
  16. Gloger S, Vöhringer PA, Martínez P, et al. The contribution of early adverse stress to complex and severe depression in depressed outpatients. Depress Anxiety. 2021;38(4):431–438. PubMed CrossRef
  17. Nelson J, Klumparendt A, Doebler P, et al. Childhood maltreatment and characteristics of adult depression: meta-analysis. Br J Psychiatry. 2017;210(2):96–104. PubMed CrossRef
  18. Botts S, Ryan M. Depression. In: Tisdale JE, Miller DA, eds. Drug-Induced Diseases: Prevention, Detection, and Management. 3rd ed. American Society of Health-System Pharmacists; 2018:375–397.
  19. Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319(22):2289–2298. PubMed CrossRef
  20. Ried LD, Tueth MJ, Taylor MD, et al. Depressive symptoms in coronary artery disease patients after hypertension treatment. Ann Pharmacother. 2006;40(4):597–604. PubMed CrossRef
  21. Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler. 2005;11(2):175–181. PubMed CrossRef
  22. National Center for Health Statistics. National Health and Nutrition Examination Survey. Cited June 20, 2017. https://www.cdc.gov/nchs/nhanes/
  23. Chen TC, Clark J, Riddles MK, et al. National Health and Nutrition Examination Survey, 2015−2018: sample design and estimation procedures. Vital Health Stat. 2(184). Cited December 16, 2020. https://www.cdc.gov/nchs/data/series/sr_02/sr02-184-508.pdf
  24. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257–263. PubMed CrossRef
  25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMed CrossRef
  26. Huang FY, Chung H, Kroenke K, et al. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med. 2006;21(6):547–552. PubMed CrossRef
  27. Andridge RR, Little RJ. A review of hot deck imputation for survey non-response. Int Stat Rev. 2010;78(1):40–64. PubMed CrossRef
  28. Eggers AC, Tuñón G, Dafoe A. Placebo tests for causal inference. 2021. https://www.semanticscholar.org/paper/Placebo-Tests-for-Causal-Inference-Eggers-Tu%C3%B1%C3%B3n/c4f3e54a0908fc1efa89d149c606fac150ed5c50
  29. Wiersema C, Oude Voshaar RC, van den Brink RHS, et al. Determinants and consequences of polypharmacy in patients with a depressive disorder in later life. Acta Psychiatr Scand. 2022;146(1):85–97. PubMed CrossRef
  30. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the US National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014;75(2):169–177. PubMed CrossRef
  31. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97–108. PubMed CrossRef
  32. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55(8):694–700. PubMed CrossRef
  33. Karp JF, Scott J, Houck P, et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry. 2005;66(5):591–597. PubMed CrossRef
  34. Lauden A, Geishin A, Merzon E, et al. Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. Brain Behav Immun Health. 2021;16:100313. PubMed CrossRef
  35. Kautzky A, Baldinger-Melich P, Kranz GS, et al. A new prediction model for evaluating treatment-resistant depression. J Clin Psychiatry. 2017;78(2):215–222. PubMed CrossRef
  36. Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014;59(7):349–357. PubMed CrossRef
  37. Fishbain DA, Cole B, Lewis JE, et al. Does pain interfere with antidepressant depression treatment response and remission in patients with depression and pain? an evidence-based structured review. Pain Med. 2014;15(9):1522–1539. PubMed CrossRef
  38. Sheng J, Liu S, Wang Y, et al. The link between depression and chronic pain: neural mechanisms in the brain. Neural Plast. 2017;2017:9724371. PubMed CrossRef
  39. Burke NN, Finn DP, Roche M. Neuroinflammatory mechanisms linking pain and depression. Mod Trends Pharmacopsychiatry. 2015;30:36–50. PubMed CrossRef
  40. Wang N, Shi M, Wang JY, et al. Brain-network mechanisms underlying the divergent effects of depression on spontaneous versus evoked pain in rats: a multiple single-unit study. Exp Neurol. 2013;250:165–175. PubMed CrossRef
  41. Max MB, Wu T, Atlas SJ, et al. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain. 2006;2:1744-8069-2-14. PubMed CrossRef
  42. Jackson JM, DeFor TA, Crain AL, et al. Validity of diabetes self-reports in the Women’s Health Initiative. Menopause. 2014;21(8):861–868. PubMed CrossRef
  43. Okura Y, Urban LH, Mahoney DW, et al. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096–1103. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now